



OPEN

An altered glial phenotype in the NL3^{R451C} mouse model of autism

Samantha M. Matta^{1,2}, Zachery Moore¹, Frederick Rohan Walker^{3,4}, Elisa L. Hill-Yardin^{2,5,6} & Peter J. Crack^{1,6}✉

Autism Spectrum Disorder (ASD; autism) is a neurodevelopmental disorder characterised by deficits in social communication, and restricted and/or repetitive behaviours. While the precise pathophysiolgies are unclear, increasing evidence supports a role for dysregulated neuroinflammation in the brain with potential effects on synapse function. Here, we studied characteristics of microglia and astrocytes in the Neuroligin-3 (NL3^{R451C}) mouse model of autism since these cell types are involved in regulating both immune and synapse function. We observed increased microglial density in the dentate gyrus (DG) of NL3^{R451C} mice without morphological differences. In contrast, WT and NL3^{R451C} mice had similar astrocyte density but astrocyte branch length, the number of branch points, as well as cell radius and area were reduced in the DG of NL3^{R451C} mice. Because retraction of astrocytic processes has been linked to altered synaptic transmission and dendrite formation, we assessed for regional changes in pre- and postsynaptic protein expression in the cortex, striatum and cerebellum in NL3^{R451C} mice. NL3^{R451C} mice showed increased striatal postsynaptic density 95 (PSD-95) protein levels and decreased cortical expression of synaptosomal-associated protein 25 (SNAP-25). These changes could contribute to dysregulated neurotransmission and cognition deficits previously reported in these mice.

Autism Spectrum Disorder (ASD; autism) is a neurodevelopmental disorder estimated to affect 1 in 54 children¹. Autism is characterised by deficits in social communication, and restricted and/or repetitive patterns of behaviour². A complex interaction between genetic and environmental factors is thought to contribute to autism. The clinical heterogeneity and variability in presentation and severity of autism has made diagnosis, treatment and the study of autism-relevant neurobiology challenging³. However, functional and neuroanatomical abnormalities are consistently reported in autism patients^{4–6}, with increasing evidence supporting a role for neuroinflammation in autism pathophysiology^{7–9}.

Neuroinflammation involves the sustained, and often unwarranted, increase in activity of glial cells (i.e. microglia and astrocytes), which release many pro-inflammatory cytokines and chemokines in response to injury, infection or disease. During this activity, ‘reactive’ microglia and astrocytes show altered morphology. Aberrant neuroimmune profiles have been documented in autism including increased densities of reactive microglia and astrocytes in several brain regions^{10–12} accompanied by alterations in cytokine and chemokine secretion in brain tissue^{10,13}, cerebrospinal fluid^{10,14} and blood^{15–17} of autism patients compared to neurotypical controls. In addition to regulating immune function, microglia and astrocytes assist in maintaining synaptic function. Abnormal glial function may therefore influence synaptic circuitry and neuronal connectivity within the central nervous system (CNS) and contribute to regional-specific under-connectivity^{6,18–21} and hyper-connectivity^{21,22} reported in autism. Given the role of glia in regulating synaptic activity, a sustained presence of reactive glial cells could contribute to cognitive and core behavioural traits in autism. It is unclear, however, whether changes to the neuronal architecture cause increased neuroinflammation, or if abnormalities in microglia and astrocytes contribute to aberrant synaptic pruning or dysfunction.

Many mutations in genes encoding synaptic proteins are implicated in autism^{23,24} including a missense mutation whereby an arginine residue is replaced by cysteine at position 451 of exon 7 of the gene encoding

¹Department of Pharmacology and Therapeutics, The University of Melbourne, Grattan St, Parkville, VIC, Australia. ²School of Health & Biomedical Sciences, RMIT University, 225-245 Clements Drive, Bundoora, VIC, Australia. ³School of Biomedical Sciences and Pharmacy, University of Newcastle, University Drive, Callaghan, NSW, Australia. ⁴Hunter Medical Research Institute, Locked Bag 1000, New Lambton, NSW, Australia. ⁵Department of Physiology, The University of Melbourne, Grattan St, Parkville, VIC, Australia. ⁶These authors contributed equally: Elisa L. Hill-Yardin and Peter J. Crack. ✉email: pcrack@unimelb.edu.au

neuroligin-3 (NL3). The R451C mutation in NL3 was identified in two brothers diagnosed with autism²⁵ and is a strong candidate gene for autism. When expressed in mice (NL3^{R451C} mice), the mutation confers behaviours relevant to the core features of autism including deficits in social interaction^{26–29}, reduced vocalisations³⁰ and repetitive behaviours^{26,31}. Several studies have demonstrated persistent phenotypic traits in NL3^{R451C} mice bred on a mixed and C57/Bl6 background^{26,27,29,32}. The R451C mutation causes a reduction in NL3 protein expression at the postsynaptic membrane to approximately 10% of control levels^{27,29}. NL3^{R451C} mice also show altered expression of other synaptic scaffolding proteins such as decreased levels of neuroligin 1 (NL1)²⁹ and increased expression of postsynaptic density protein 95 (PSD-95) and synapse-associated protein-102 (SAP-102)²⁷. These changes occur alongside an imbalance in excitatory and inhibitory synaptic transmission^{27,29,33–35}.

Here, we hypothesised that NL3^{R451C} mice exhibit altered microglial and astrocyte morphology indicative of a reactive state as well as changes in synaptic protein levels. We first assessed for changes in neuroinflammation by investigating the density and morphology of hippocampal microglia and astrocytes in WT and NL3^{R451C} mice. We then explored alterations to synapse structure through analysis of synaptic proteins involved in neuronal signalling.

Results

Microglial density was increased in the DG region of NL3^{R451C} mice compared to WT. In the CA1, microglia somata were elongated in NL3^{R451C} compared to WT mice but did not exhibit any other morphology changes. Astrocyte density was also similar in the hippocampal CA1 and DG regions in NL3^{R451C} and WT mice. Although astrocyte morphological parameters were unchanged in the CA1 region, in the DG, astrocytic branch length, the number of branches, cell radius and cell area measures were decreased in NL3^{R451C} mice. Interestingly, postsynaptic density 95 (PSD-95) protein levels were elevated in the striatum, whereas cortical levels of the presynaptic protein, synaptosomal-associated protein 25 (SNAP-25) were decreased in NL3^{R451C} mice.

Increased hippocampal microglial density in NL3^{R451C} mice. We observed increased microglial density in the DG region (Fig. 1) of the hippocampus in NL3^{R451C} mice compared to WT (Table 1). There was also a non-significant trend for increased density of microglia in the CA1 hippocampal region (Fig. 2). Microglial cell morphology was similar between genotypes with no changes in branching (number of primary branches, number of branch points, or total branch length) or cell size (cell radius or cell area). Although soma area was similar between genotypes, soma eccentricity was increased in the CA1 region of NL3^{R451C} mice.

Reduced cell size and branch length in Dentate Gyrus astrocytes in NL3^{R451C} mice. Hippocampal DG (Fig. 3) and CA1 (Fig. 4) astrocytes were present at similar cell densities in WT and NL3^{R451C} mice (Table 2). DG astrocytes, however, showed an altered morphology, with decreased number of branch points, total branch length, cell radius and cell area in NL3^{R451C} mice compared to WT. The total number of primary branches of DG astrocytes was not changed in NL3^{R451C} mice. Astrocyte cellular parameters were similar between NL3^{R451C} and WT mice in the CA1 region.

Region-specific changes in synaptic structural proteins in NL3^{R451C} mice. We next investigated the structure of synapses by analysing expression levels of presynaptic (i.e. dendritic; PSD-95, PSD-93 and Neuroligin 2 (NL2); Fig. 5) and postsynaptic (axonal; SNAP-25 and synaptotagmin-1 (SYT-1); Fig. 6) proteins in cortical, striatal and cerebellar tissue samples of WT and NL3^{R451C} mice (Table 3). PSD-95 was increased significantly in the striatum (Fig. 5C,D) and SNAP-25 was decreased significantly in the cortex (Fig. 6G,H) of NL3^{R451C} mice compared to WT. As expected, Neuroligin 3 protein expression was dramatically decreased in all regions analysed in NL3^{R451C} mice (Supplementary Fig. S5). Moreover, in agreement with our GFAP immunofluorescence findings of similar hippocampal astrocyte density in WT and NL3^{R451C} brain slices, we observed no change in GFAP expression levels in WT and NL3^{R451C} cortical, striatal or cerebellar brain lysates (Fig. 7) using Western blot. The original, full-length images of the Western blots have been added to our supplementary information, as Figures S6–S9.

Discussion

Microglia and astrocyte profiles are subtly altered in NL3^{R451C} mice. These changes differ from previously reported morphological changes thought to indicate a reactive microglial state^{36,37}. Namely, microglia in NL3^{R451C} mice did not show process retraction or thickening of ramified processes. In addition, astrocytes did not show hypertrophy or branch extension typically associated with a reactive inflammatory state^{36,37}. Interestingly, we observed increased microglial cell density in the DG, and a trend for increased density in the CA1 region, of the hippocampus in NL3^{R451C} mice. Although increased microglial density is typically seen in conjunction with increased reactivity^{11,38}, increased microglial density has also been reported prior to the reactive state in a mouse model of Alzheimer's disease³⁹. Rodriguez and colleagues reported an increased density of ramified microglia in the CA1 region of the hippocampus preceding the formation of amyloid β plaques and morphological changes of microglia to a reactive phenotype in a triple-transgenic model of Alzheimer's disease³⁹. Although it is well established that reactive microglia show soma elongation, in the CA1 region of NL3^{R451C} mice we report increased microglial soma eccentricity but no change in other parameters relevant to the reactive state such as soma area, cell size or branching patterns. The microglial soma elongation in NL3^{R451C} mice may indicate a subtle physiological functional change in this cell type, however the precise role of this morphological change in the absence of an inflammatory insult is unclear.

In the DG, we identified a significant decrease in both the number of branch points and the length of astrocyte processes in NL3^{R451C} mutants compared to WT mice. Similarly, significant decreases in measures of cell radius




Figure 1. Microglial cell density is increased in the DG hippocampal region in NL3^{R451C} mice. Representative confocal immunofluorescence images of DG hippocampal coronal sections from WT (A–D) and NL3^{R451C} (E–H) mice co-labelled with IBA-1 (red), NeuN (green) and DAPI (blue). Scale bar = 50 μm. (I–P) Number of IBA-1 immunoreactive cells, branching parameters, cell radius, cell area, soma area and soma eccentricity in WT and NL3^{R451C} mice (n=5 mice in each group). Data represented as mean ± SEM.

and cell area in DG astrocytes were observed. This may indicate an alteration in the local environment which leads to a subsequent change in cell morphology. Surprisingly, these findings contrast with the morphological changes characteristic of reactive astrocytes, such as an extension and thickening of processes and somatic hypertrophy. Astrocytic processes maintain contact with neuronal synapses and regulate neuronal function as part of the tripartite synapse⁴⁰. Astrocytes also contribute to regulating neurotransmitter concentrations at the synapse through the uptake of the excitatory neurotransmitter glutamate via excitatory amino acid transporters expressed on the astrocytic cell membrane. Prolonged retraction of astrocytic processes could therefore reduce glutamate uptake from the synaptic cleft and alter neurotransmission⁴¹. Moreover, astrocytic processes interacting with the synapse can prevent synapse growth during memory consolidation, highlighting the significance of astrocyte morphology in synapse function and cognition⁴². For example, astrocyte contact with dendrites regulates the formation, length and survival of dendritic spine protrusions, via pathways involving Ras-related C3 botulinum toxin substrate 1 (Rac1) and ephrin-A3⁴³. In addition, retraction and disengagement of astrocytic processes from postsynaptic dendritic spines can decrease the survival rate and maturation of dendrites⁴⁴. As such, our observations could therefore be associated with the formation of immature dendritic spines and disrupted synaptic communication as well as the enhanced motor^{26,31} and spatial learning^{28,29} seen in this model. Relevant to our findings, an increase in dendritic branching but decreased spine area has also been reported in the CA1 region of the hippocampus in NL3^{R451C} mice²⁷.

Cell parameters	WT mean	NL3 mean	p-value	Significance
Hippocampal DG region				
Cell density (cells/mm ²)	22.6±4	38.7±4	0.018	*
No. of primary branches	3.79±0.2	3.87±0.3	0.83	NS
No. of branch points	4.61±0.8	5.28±1.0	0.62	NS
Total branch length (μm)	153±21.8	152±16.9	0.97	NS
Cell radius (μm)	34.2±2.5	34.8±2.0	0.85	NS
Cell area (μm ²)	249±33.2	250±17.5	0.99	NS
Soma area (μm ²)	48.3±4	49.2±4	0.89	NS
Soma eccentricity	0.79±0.04	0.87±0.004	0.08	NS
Hippocampal CA1 region				
Cell density (cells/mm ²)	20.28±2.1	30.19±3.5	0.064	NS
No. of primary branches	3.99±0.4	3.94±0.2	0.90	NS
No. of branch points	4.68±1.1	5.32±1.2	0.70	NS
Total branch length (μm)	167±34	160±30	0.87	NS
Cell radius (μm)	24.0±3	22.9±2	0.79	NS
Cell area (μm ²)	265.0±39	282.0±53	0.80	NS
Soma area (μm ²)	50.5±5	56.7±7	0.46	NS
Soma eccentricity	0.79±0.02	0.86±0.01	0.024	*

Table 1. Analysis of microglial density and morphology in the hippocampus. NS not significant. *p<0.05.

Glial cells are involved in the physiological maintenance of synapses, including the removal, or pruning, of dendrites and axons following prolonged inactivity. Therefore, we next investigated the expression of synaptic structural proteins to determine if synaptic pruning may be altered in this model. Although we found that expression of the majority of synaptic proteins examined were unaffected, regional-specific alterations in expression of cortical SNAP-25 and striatal PSD-95 support previous reports of changes in synapse structure in NL3^{R451C} mice.

Decreased expression of NL1 has previously been reported in NL3^{R451C} mice⁴⁹, but we observed no difference in neuroligin 2 (NL2) protein expression. These observations may be due to differences in the synaptic localisation and function of NL1 and NL2 and their interactions with NL3. NL1 is localised to glutamatergic excitatory postsynapses⁴⁵ whereas NL2 is found at GABAergic inhibitory postsynaptic boutons⁴⁶. NL3 forms heterodimers with NL1 but not NL2⁴⁷. Since the R451C mutation causes a drastic reduction in NL3 protein expression, we propose that decreased NL1 levels may occur in NL3^{R451C} mice due to the reduced levels of NL3 available to bind with NL1.

The postsynaptic density proteins (PSD) PSD-93 and PSD-95 influence neurotransmission via their roles as scaffolding proteins at excitatory synapses as well as by binding NMDA receptors and recruiting AMPA receptors⁴⁸. PSD-95 also binds to neuroligins to facilitate the recruitment of ion channels and receptors to the synapse^{49,50}. NL3^{R451C} mice show increased expression of PSD-95 in the hippocampus²⁷. In the current study, we confirm these findings via our analysis of PSD-95 protein levels in striatal brain tissue, comprising the hippocampus in addition to the thalamus, amygdala and corpus callosum. Here, we report that elevated PSD-95 protein expression is exclusive to the striatum, as we observed no significant changes in PSD-95 abundance in the cortex or cerebellum despite the expected dramatic decrease in NL3 in all brain regions analysed. Our observations of increased microglial density in the hippocampus may contribute to dysregulation of synaptic maintenance in NL3^{R451C} mice.

Our data show brain region-specific changes in synaptic protein expression in NL3^{R451C} mutant mice. We assayed expression levels of presynaptic proteins, SYT-1 and SNAP-25, which are involved in facilitating neurotransmitter release⁵¹ and mutations in these genes have been identified in autism patients⁵². Individuals with missense variants in SYT-1 are reported to exhibit impaired social development, motor stereotypies and developmental delay⁵³. A number of studies have also reported single nucleotide polymorphisms in SNAP-25 that are associated with increased severity of core behaviours and hyperactivity^{54,55}, and are associated with cognitive deficits⁵⁶ in autism. Although SYT-1 abundance was unchanged, SNAP-25 protein levels were significantly decreased in the cortex of NL3^{R451C} mice. SNAP-25 expression has not been previously investigated in this model to our knowledge. Beyond its role in the presynaptic initiation of neuronal signalling and association with autism-relevant behaviours, SNAP-25 influences dendritic spine formation via binding to the postsynaptic protein, p140Cap⁵⁷. Reduced expression of SNAP-25 results in immature dendritic spine formation, specifically involving a decrease in the number of shorter, wider spines, and an increased proportion of longer filopodia⁵⁷. As reported by Tomasoni et al.⁵⁷, these changes were accompanied by a decrease in PSD-95 density and rescued following over-expression of SNAP-25. These findings are relevant given that microglial processes engulf pre- and postsynaptic proteins during synapse maturation in mice. Highlighting this interaction, both PSD-95 and SNAP-25 have been localised to microglia in the CA1 hippocampal region of mice at postnatal day 15⁵⁸. In our analysis, a reduction in cortical SNAP-25 levels was accompanied by a trend for reduced PSD-95 expression in NL3^{R451C} mice, consistent with a potential increase in microglial engulfment of cortical synapses and altered dendrite spine morphology²⁷.




Figure 2. Soma eccentricity is increased in the CA1 hippocampal region in NL3^{R451C} mice. Representative confocal immunofluorescence images of CA1 hippocampal coronal sections from WT (A–D) and NL3^{R451C} (E–H) mice co-labelled with IBA-1 (red), NeuN (green) and DAPI (blue). Scale bar = 50 μm. (I–P) Number of IBA-1 immunoreactive cells, branching parameters, cell radius, cell area and soma area and soma eccentricity in WT and NL3^{R451C} mice (n=5 mice in each group). Data represented as mean ± SEM; *p = < 0.05.

This study is the first to identify an increased density of DG hippocampal microglia and decreased expression of cortical SNAP-25 in the NL3^{R451C} mouse model of autism. These initial findings suggest a potential role for microglia, PSD-95 and SNAP-25 in the pathophysiology observed in NL3^{R451C} mice. Although the microglial and astrocytic profiles observed here differ from those associated with immune responses as reported in other rodent models, these subtle changes may predispose NL3^{R451C} mice to an aberrant response in the context of immune stimuli. Furthermore, this phenotype could indicate a role for microglia and astrocytes in altered synapse function in NL3^{R451C} mice. Due to its multi-faceted roles in regulating presynaptic function and postsynaptic dendritic structure, SNAP-25 is a potential candidate target for personalized therapeutic strategies in the treatment of ASD. Collectively, we identified changes to astrocyte morphology that could be involved in mediating previously reported changes in synaptic transmission and dendritic branching in NL3^{R451C} mice³⁴. Further characterisation of neuroimmune function in NL3^{R451C} mice is required to advance the understanding of biological mechanisms contributing to autism.

Methods

Animals. Immunohistochemical and western blot analyses were performed on tissue from NL3^{R451C} and WT mice. Mice were bred on a Sv129/ImJ/C57Bl6 or a pure C57/Bl6 genetic background. B6; 129-Nlgn3^{tm1Sud}/J mice were obtained from Jackson Laboratories (USA) and maintained on a Sv129/ImJ/C57Bl6 background. C57/




Figure 3. Astrocytic cell density is unchanged, but show lessened number of branch points, retracted processes and decreases in cell radius and cell area in the DG of the hippocampus in $\text{NL3}^{\text{R451C}}$ mice. Representative confocal immunofluorescence images of DG hippocampal coronal sections from WT (A–D) and $\text{NL3}^{\text{R451C}}$ (E–H) mice co-labelled with GFAP (green), NeuN (red) and DAPI (blue). Scale bar = 50 μm . (I–P) Number of GFAP immunoreactive cells, branching parameters, cell radius and GFAP labelled cell area ($n=5$ mice in each group). Data represented as mean \pm SEM; * $p < 0.05$, ** $p < 0.01$.

Bl6 mice were generated after backcrossing onto a pure C57/Bl6 strain for more than 10 generations. Mutant mice express the R451C substitution (arginine to cysteine on residue 451) in exon 7 of the X-linked neuroligin 3 (NL3) gene. Females heterozygous for the $\text{NL3}^{\text{R451C}}$ mutation were mated with WT males to generate WT and $\text{NL3}^{\text{R451C}}$ offspring. Only male mice were utilised in these experiments due to the higher prevalence of ASD in males. Mice were housed in mixed genotype groups of up to five per cage on a 12:12 h light/dark cycle, with food and water provided ad libitum. Tail and ear clips were obtained pre-weaning at 3 weeks for genotyping. Genotyping was performed in-house via PCR analysis as previously described²⁹. All experiments were approved by the University of Melbourne Animal Ethics Committee (Ethics ID: 1613990.1) and were conducted in line with the Australian code of practice for the care and use of animals for scientific purposes. C57/Bl6 WT and $\text{NL3}^{\text{R451C}}$ mice used for Western blot analysis were collected at 3 months of age and killed via cervical dislocation ($n=6$ for each genotype). Mixed background WT and $\text{NL3}^{\text{R451C}}$ mice used for immunohistochemical analysis aged 2 to 5 months old were anaesthetised and underwent cardiac perfusion with 4% paraformaldehyde ($n=5$ for each genotype, detailed below).

Immunohistochemistry. Mice were anaesthetised via intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg) and perfused transcardially with phosphate buffered saline (PBS; pH 7.4) followed by 4% paraformaldehyde in PBS. The brain was excised and post-fixed for a further 24 h at 4 °C. Brain tissue was




Figure 4. Astrocytic cell density and morphology are unchanged in the CA1 hippocampal region in NL3^{R451C} mice. Representative confocal immunofluorescence images of CA1 hippocampal coronal sections from WT (A–D) and NL3^{R451C} (E–H) mice co-labelled with GFAP (green), NeuN (red) and DAPI (blue). Scale bar represents 50 μm. (I–P) Number of GFAP immunoreactive cells, branching parameters, cell radius and GFAP labelled cell area ($n=5$ mice in each group). Data represented as mean \pm SEM.

subsequently rinsed three times in phosphate buffered saline (PBS) and cryopreserved in 30% sucrose in PBS for at least 24 h at 4 °C. Brains were embedded in optimal cutting temperature (OCT) compound in 2 cm³ aluminium foil moulds, submerged partially in isopentane and frozen in liquid nitrogen to prepare for cryosectioning. Moulds were stored at –80 °C until use.

Coronal sections (30 μm thickness) were cut on a cryostat machine (Reichert-Jung, USA) at –23 °C until the hippocampal region was reached at bregma -1.955 mm (Allen Reference Atlas). Tissue sections from WT and NL3^{R451C} mice were stained with either the microglial marker, IBA-1 (Ionized calcium-Binding Adapter molecule-1) or the astrocyte marker, GFAP (Glial Fibrillary Acidic Protein) and co-labelled with neuronal marker, NeuN (Neuronal Nuclei) to detect glial cells and neurons in the hippocampus (Table 4). DAPI was used as a counterstain to clarify the cellular organisation of each brain region.

Free-floating sections were washed (3 × 5 min) and blocked for 1.5 h (for IBA-1) or 3 h (for GFAP) in 1.5% Triton goat block (1 ml goat serum; 9 ml PBS; 150 μl Triton-X (Sigma-Aldrich, Germany)) with constant rocking. Sections were washed (3 × 5 min) and incubated with primary antibodies overnight at 4 °C with constant rocking before being washed (3 × 5 min) and incubated with the corresponding secondary antibodies for 1.5 h in a dark environment with constant rocking. Sections were mounted onto Menzel-Glaser SuperFrost Plus (Thermo Scientific, USA) or regular (Sail Brand, China) microscope slides with Vectashield hard-set mounting medium containing 4', 5-diamidino-2-phenylindole (DAPI) (Abacus ALS, Australia). Multi-channel images of the DG and CA1 hippocampal regions were taken at 20× magnification (tissue area imaged was 424 μm²) on an

Cell parameters	WT mean	NL3 mean	p-value	Significance
Hippocampal DG region				
Cell density (cells/mm ²)	66.1 ± 9	94.8 ± 16	0.16	NS
No. of primary branches	4.96 ± 0.3	4.29 ± 0.2	0.12	NS
No. of branch points	5.84 ± 0.7	2.87 ± 0.6	0.01	*
Total branch length (μm)	167 ± 15	96.8 ± 13	0.007	**
Cell radius (μm)	34.8 ± 1.5	22.7 ± 1.5	0.01	*
Cell area (μm ²)	254.0 ± 18	169.0 ± 14	0.005	**
Hippocampal CA1 region				
Cell density (cells/mm ²)	53.3 ± 4.0	56.6 ± 6.0	0.72	NS
No. of primary branches	5.79 ± 0.3	5.62 ± 0.3	0.69	NS
No. of branch points	5.96 ± 1.0	6.40 ± 1.0	0.76	NS
Total branch length (μm)	185.0 ± 22	204.0 ± 27	0.60	NS
Cell radius (μm)	37.1 ± 3	39.1 ± 2	0.55	NS
Cell area (μm ²)	279.0 ± 33	308.0 ± 33	0.56	NS

Table 2. Analysis of astrocyte density and morphology in the hippocampus. NS not significant. *p < 0.05, **p < 0.01.

LSM880 Airyscan microscope (Zeiss, Germany) at the Biological Optical Microscopy Platform (BOMP), The University of Melbourne, Australia.

Cell counts and morphological analysis. Cell counts and morphological analysis of microglia and astrocytes was performed using a proprietary method within MATLAB v12.0 as described previously^{59,60}. Briefly, the analysis generates intensity quantiles across an image to locate individual cell somas, traces cell processes outwards, then quantifies the resultant image (Supplementary Figs. S1–S4). Minimum object detection (i.e. soma) size was set at 100–200 pixels. Quantile levels for both soma and background intensity were manually adjusted in order to normalise fluorescence intensity between tissue samples. The resulting optimal intensity level enabled clear detection of signal intensities in contrast with low levels of background labelling. The entire field of view (424 μm²) of the regions of interest (hippocampal DG and CA1) were counted at ×20 magnification.

Western blot analysis. Mice were killed via cervical dislocation prior to decapitation and brains excised. Brain tissue from the left hemisphere was divided in cortical, striatal and cerebellar tissue samples and for Western blot analysis. Tissue was suspended in 900 μl of homogenisation buffer (9.88 ml Milli-Q H₂O, 125 μl 1 M Tris HCl pH 7.4, 2.5 ml 10% sodium dodecyl sulfate (SDS), 1 tablet PhosSTOP phosphatase inhibitor (Roche, Switzerland), 1 tablet cComplete protease inhibitor (Roche)) using a homogenising pestle and sonication (15 × 1 s pulses). Protein samples were gently rotated in a rotary suspension mixer at 4 °C for 1.5 h. Samples were centrifuged (Eppendorf Centrifuge 5424 R, Germany; 15 min at 12,000 rpm) and the colourless supernatant extracted. A Bradford Protein Assay (BioRad, USA) was performed to determine the total protein content of the brain lysates as per manufacturer's instructions. Protein samples were diluted in sample buffer (5% β-mercaptoethanol (v/v) (Sigma-Aldrich) in 2 × Tris-Glycine SDS loading buffer (Invitrogen, USA)) to achieve a final concentration of 2 μg/μl. Samples were heated at 95 °C for 15 min to denature the proteins and stored at -20 °C until use.

10 μl of brain lysate samples (for a final protein concentration of 20 μg/μl) and 5 μl of the pre-stained molecular weight ladder (BioRad) (8% gel: 25–250 kDa; 12% gel: 10–70 kDa) were loaded on an 8% resolving gel (per four gels: 10 ml 1.5 M Tris-HCl (BioRad), 400 μl 10% (w/v) SDS (BioRad), 18.98 ml Milli-Q H₂O, 10.67 ml 30% Acrylamide/Bis solution (BioRad), 600 μl 10% (w/v) Ammonium Persulfate (APS, Sigma-Aldrich) in Milli-Q H₂O, 60 μl N,N,N',N'-tetramethylmethane-1,2-diamine (TEMED, BioRad)) or 12% resolving gel (per four gels: 10 ml 1.5 M Tris-HCl, 400 μl 10% (w/v) SDS, 13.16 ml Milli-Q H₂O, 16 ml 30% Acrylamide/Bis solution, 600 μl 10% APS in Milli-Q H₂O, 40 μl TEMED). Proteins were separated by SDS-PAGE at 80/120 V in Tris-Glycine SDS-PAGE running buffer (Life Technologies, USA). The separated sample proteins in the gel were transferred onto a Polyvinylidene fluoride (PVDF) membrane via a semi-dry transfer which was run at 60 mA/gel for 75 min, facilitated by a transfer buffer (20 ml of 25 × Tris-glycine transfer buffer (Life Technologies), 50 ml 100% methanol, 430 ml Milli-Q H₂O). The PVDF membrane was then blocked in 5% (w/v) skim milk in Tris Buffer Solution Tween 20 (TBS-T; 5% Tween-20 (v/v) in TBS) for 1 h at RT with constant rotation. Membranes were washed (3 × 10 min) and incubated in the primary antiserum diluted in TBS-T (Table 5) overnight at 4 °C. The membrane was washed (3 × 10 min) then incubated in the corresponding horseradish peroxidase (HRP)-conjugated secondary antiserum diluted in TBS-T for 1.5 h at RT.

Membranes were imaged using a ChemiDoc XRS + system (BioRad) and protein bands were visualised using the electrochemiluminescence (ECL) prime detection kit (Amersham, USA). To determine whether the total protein content was constant across samples, β-actin was used as a loading control. Optical density of the bands was analysed via densitometric analysis using ImageJ software (version 2.0.0-rc-68/1.52e; NIH, USA), and arbitrary intensity units were compared by calculating the expression of the antiserum of interest relative to the loading control (β-actin), and averaged for both the WT and NL3^{R451C} genotypes. Mean protein expression values for




Figure 5. PSD-95 protein levels are increased in the striatum of NL3^{R451C} mice, whereas PSD-93 and NL2 expression is unchanged. Levels of postsynaptic proteins, PSD-95, PSD-93 and NL2 in cortical (A,G,M), striatal (C,I,O) and cerebellar (E,K,Q) brain lysates from NL3^{R451C} and WT mice were analysed via Western blot. Densitometric analysis was performed to demonstrate quantitative expression of PSD-95 (B,D,F), PSD-93 (H,J,L) and NL2 (N,P,R) relative to β actin expression. Genotype differences were analysed using an unpaired, two-tailed Student's t-test ($n=6$ mice in each group); * $p<0.05$. Data represented as mean ± SEM.

WT mice were normalized to 100% for each blot and NL3^{R451C} protein expression levels were compared as a percentage relative to control (WT).

Statistical analysis. Statistical analysis was performed using Prism software (Graphpad v6.0c; USA). All cell datasets were assessed for normality with the Kolmogorov-Smirnov test for normality with the Dallal-Wilkinson-Lilliefors correction. For datasets that passed the normality test, potential differences between samples from the two genotypes were analysed using a two-tailed, unpaired Student's t-test. Datasets that failed to




Figure 6. SYT-1 protein levels are unchanged, but SNAP-25 protein expression was decreased in the cortex of $\text{NL3}^{\text{R451C}}$ mice. SYT-1 and SNAP-25 protein expression in cortical (A,G), striatal (C,I) and cerebellar (E,K) lysates from $\text{NL3}^{\text{R451C}}$ and WT mice were analysed via Western blot. Densitometric analysis was performed to demonstrate quantitative expression of SYT-1 (B,D,F) and SNAP-25 (H,J,L) relative to β actin expression. Genotype differences were analysed using an unpaired, two-tailed Student's t-test ($n=6$ mice in each group); $^{**}p<0.01$. Data represented as mean \pm SEM.

Synaptic protein	Expression in $\text{NL3}^{\text{R451C}}$ mice compared to WT		
	Cortex	Striatum	Cerebellum
PSD-95	$81 \pm 3.2\%$ $p = 0.071$	$129 \pm 8.6\%$ $p = 0.01^*$	$101 \pm 7.6\%$ $p = 0.95$
PSD-93	$93 \pm 9.5\%$ $p = 0.58$	$83 \pm 9.7\%$ $p = 0.28$	$106 \pm 8.8\%$ $p = 0.66$
NL2	$90 \pm 10\%$ $p = 0.52$	$102 \pm 5.7\%$ $p = 0.80$	$117 \pm 18\%$ $p = 0.45$
SYT-1	$103 \pm 6.8\%$ $p = 0.79$	$77 \pm 6.9\%$ $p = 0.092$	$160 \pm 23\%$ $p = 0.12$
SNAP-25	$67 \pm 4.8\%$ $p = 0.003^{**}$	$85 \pm 6.8\%$ $p = 0.28$	$105 \pm 13\%$ $p = 0.78$
GFAP	$72 \pm 12\%$ $p = 0.27$	$96 \pm 11\%$ $p = 0.84$	$74 \pm 14\%$ $p = 0.32$

Table 3. Analysis of synaptic protein expression. The bold, italics font highlights statistically significant differences between genotypes: * $p < 0.05$, ** $p < 0.01$.

meet a normal distribution (CA1 microglial density and CA1 astrocyte density) were assessed using a two-tailed Mann-Whitney U test. For Western blot analysis, all expression levels in $\text{NL3}^{\text{R451C}}$ mutant tissue were compared to WT levels (normalised to 100) and analysed with a two-tailed unpaired Student's t-test. Data was presented as mean \pm SEM; p-values less than 0.05 were considered to represent statistical differences between genotypes.




Figure 7. GFAP protein levels are unchanged in NL3^{R451C} mice. Cortical (A), striatal (C) and cerebellar (E) lysates from NL3^{R451C} and WT mice were analysed via Western blot. Densitometric analysis was performed to demonstrate quantitative expression of GFAP relative to β actin expression (B,D,F). Genotype differences were analysed using an unpaired, two-tailed Student's t-test ($n=6$ mice in each group). Data represented as mean ± SEM.

Primary antiserum	Supplier	Dilution	Secondary antiserum	Supplier	Dilution
Rabbit polyclonal anti-GFAP	Dako #Z0334	1:500	Goat anti-rabbit IgG Alexa Fluor 488	Invitrogen #A-11008	1:2000
Rabbit polyclonal anti-IBA-1	Novachem #01919741	1:200	Goat anti-rabbit IgG Alexa Fluor 594	Invitrogen #A-11012	1:2000
Mouse monoclonal anti-NeuN	Abcam #ab104225	1:2000	For GFAP: Goat anti-mouse IgG Alexa Fluor 594 For IBA-1: Goat anti-mouse IgG Alexa Fluor 488	Invitrogen #A-11005 Invitrogen #A-11001	1:2000 1:2000

Table 4. Antibodies used in immunohistochemical analysis.

Primary antiserum	Supplier	Dilution	Secondary antiserum	Supplier	Dilution
Rabbit polyclonal anti-NL3 (110 kDa)	Synaptic systems #129113	1:500	Goat anti-rabbit IgG HRP Dako #P0048	1:1,000	
Rabbit polyclonal anti-PSD-93 (110 kDa)	Alomone Labs #APZ002	1:500			
Rabbit polyclonal anti-NL2 (91 kDa)	Synaptic systems #129203	1:500			
Rabbit polyclonal anti-SYT-1 (48 kDa)	Alomone Labs #ANR-003	1:500			
Rabbit polyclonal anti-GFAP (48 kDa)	Dako #Z0334	1:5,000			
Rabbit polyclonal anti-SNAP-25 (23 kDa)	Alomone Labs #ANR-001	1:500			
Mouse monoclonal anti-PSD-95 (95 kDa)	UC Davis/NIH NeuroMab Facility #K28/43	1:5,000			
Mouse monoclonal anti-β-actin (42 kDa)	Sigma-Aldrich #A5441	1:4,000			

Table 5. Antibodies used in Western blot analysis.

Received: 23 March 2020; Accepted: 26 June 2020
Published online: 02 September 2020

References

- Maenner, M. J. et al. Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2016. *MMWR Surveill. Summ.* **69**, 1–12. <https://doi.org/10.15585/mmwr.ss6904a1> (2020).
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders* 5th edn. (American Psychiatric Association, Philadelphia, 2013).

3. Jeste, S. S. & Geschwind, D. H. Disentangling the heterogeneity of autism spectrum disorder through genetic findings. *Nat. Rev. Neurosci.* **10**, 74–81. <https://doi.org/10.1038/nrneurol.2013.278> (2014).
4. Amaral, D. G., Schumann, C. M. & Nordahl, C. W. Neuroanatomy of autism. *Trends Neurosci.* **31**, 137–145. <https://doi.org/10.1016/j.tins.2007.12.005> (2008).
5. Minshew, N. J. & Williams, D. L. The new neurobiology of autism: cortex, connectivity, and neuronal organization. *Arch. Neurol.* **64**, 945–950. <https://doi.org/10.1001/archneur.64.7.945> (2007).
6. Assaf, M. *et al.* Abnormal functional connectivity of default mode sub-networks in autism spectrum disorder patients. *Neuroimage* **53**, 247–256. <https://doi.org/10.1016/j.neuroimage.2010.05.067> (2010).
7. Onore, C., Careaga, M. & Ashwood, P. The role of immune dysfunction in the pathophysiology of autism. *Brain Behav. Immun.* **26**, 383–392. <https://doi.org/10.1016/j.bbi.2011.08.007> (2012).
8. Pardo, C. A., Vargas, D. L. & Zimmerman, A. W. Immunity, neuroglia and neuroinflammation in autism. *Int. Rev. Psychiatry* **17**, 485–495. <https://doi.org/10.1080/02646830500381930> (2005).
9. Matta, S. M., Hill-Yardin, E. L. & Crack, P. J. The influence of neuroinflammation in Autism Spectrum Disorder. *Brain Behav. Immun.* <https://doi.org/10.1016/j.bbi.2019.04.037> (2019).
10. Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W. & Pardo, C. A. Neuroglial activation and neuroinflammation in the brain of patients with autism. *Ann. Neurol.* **57**, 67–81. <https://doi.org/10.1002/ana.20315> (2005).
11. Morgan, J. T. *et al.* Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. *Biol. Psychiatry* **68**, 368–376. <https://doi.org/10.1016/j.biopsych.2010.05.024> (2010).
12. Tetreault, N. A. *et al.* Microglia in the cerebral cortex in autism. *J. Autism Dev. Disord.* **42**, 2569–2584. <https://doi.org/10.1007/s10803-012-1513-0> (2012).
13. Li, X. *et al.* Elevated immune response in the brain of autistic patients. *J. Neuroimmunol.* **207**, 111–116. <https://doi.org/10.1016/j.jneuroim.2008.12.002> (2009).
14. Chez, M. G., Dowling, T., Patel, P. B., Khanna, P. & Kominsky, M. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. *Pediatr. Neurol.* **36**, 361–365. <https://doi.org/10.1016/j.pediatrneurol.2007.01.012> (2007).
15. Xie, J. *et al.* Immunological cytokine profiling identifies TNF-alpha as a key molecule dysregulated in autistic children. *Oncotarget* **8**, 82390–82398. <https://doi.org/10.18632/oncotarget.19326> (2017).
16. Gupta, S., Aggarwal, S., Rashanravan, B. & Lee, T. Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. *J. Neuroimmunol.* **85**, 106–109 (1998).
17. Ashwood, P. *et al.* Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders. *J. Neuroimmunol.* **232**, 196–199. <https://doi.org/10.1016/j.jneuroim.2010.10.025> (2011).
18. Just, M. A., Cherkassky, V. L., Keller, T. A., Kana, R. K. & Minshew, N. J. Functional and anatomical cortical underconnectivity in autism: evidence from an fMRI study of an executive function task and corpus callosum morphometry. *Cereb. Cortex* **17**, 951–961. <https://doi.org/10.1093/cercor/bhl006> (2007).
19. Just, M. A., Cherkassky, V. L., Keller, T. A. & Minshew, N. J. Cortical activation and synchronization during sentence comprehension in high-functioning autism: evidence of underconnectivity. *Brain* **127**, 1811–1821. <https://doi.org/10.1093/brain/awh199> (2004).
20. Koshino, H. *et al.* fMRI investigation of working memory for faces in autism: visual coding and underconnectivity with frontal areas. *Cereb. Cortex* **18**, 289–300. <https://doi.org/10.1093/cercor/bhm054> (2008).
21. Kleinhans, N. M. *et al.* Abnormal functional connectivity in autism spectrum disorders during face processing. *Brain* **131**, 1000–1012. <https://doi.org/10.1093/brain/awm334> (2008).
22. Supekar, K. *et al.* Brain hyperconnectivity in children with autism and its links to social deficits. *Cell Rep.* **5**, 738–747. <https://doi.org/10.1016/j.celrep.2013.10.001> (2013).
23. Leblond, C. S. *et al.* Meta-analysis of SHANK mutations in autism spectrum disorders: a gradient of severity in cognitive impairments. *PLoS Genet.* **10**, e1004580. <https://doi.org/10.1371/journal.pgen.1004580> (2014).
24. Arking, D. E. *et al.* A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism. *Am. J. Hum. Genet.* **82**, 160–164. <https://doi.org/10.1016/j.ajhg.2007.09.015> (2008).
25. Jaramillo, S. *et al.* Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. *Nat. Genet.* **34**, 27–29. <https://doi.org/10.1038/ng1136> (2003).
26. Burrows, E. L. *et al.* A neuroligin-3 mutation implicated in autism causes abnormal aggression and increases repetitive behavior in mice. *Mol. Autism* **6**, 62. <https://doi.org/10.1186/s13229-015-0055-7> (2015).
27. Etherton, M. *et al.* Autism-linked neuroligin-3 R451C mutation differentially alters hippocampal and cortical synaptic function. *Proc. Natl. Acad. Sci. USA* **108**, 13764–13769. <https://doi.org/10.1073/pnas.1111093108> (2011).
28. Jaramillo, T. C., Liu, S., Pettersen, A., Birnbaum, S. G. & Powell, C. M. Autism-related neuroligin-3 mutation alters social behavior and spatial learning. *Autism Res.* **7**, 264–272. <https://doi.org/10.1002/aur.1362> (2014).
29. Tabuchi, K. *et al.* A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. *Science* **318**, 71–76. <https://doi.org/10.1126/science.1146221> (2007).
30. Radyushkin, K. *et al.* Neuroligin-3-deficient mice: model of a monogenic heritable form of autism with an olfactory deficit. *Genes Brain Behav.* **8**, 416–425. <https://doi.org/10.1111/j.1601-183X.2009.00487.x> (2009).
31. Rothwell, P. E. *et al.* Autism-associated neuroligin-3 mutations commonly impair striatal circuits to boost repetitive behaviors. *Cell* **158**, 198–212. <https://doi.org/10.1016/j.cell.2014.04.045> (2014).
32. Hosie, S. *et al.* Altered amygdala excitation and CB1 receptor modulation of aggressive behavior in the neuroligin-3(R451C) mouse model of autism. *Front. Cell. Neurosci.* **12**, 234. <https://doi.org/10.3389/fncel.2018.00234> (2018).
33. Zhang, B. *et al.* Developmental plasticity shapes synaptic phenotypes of autism-associated neuroligin-3 mutations in the calyx of Held. *Mol. Psychiatry* **22**, 1483–1491. <https://doi.org/10.1038/mp.2016.157> (2017).
34. Pizzarelli, R. & Cherubini, E. Developmental regulation of GABAergic signalling in the hippocampus of neuroligin 3 R451C knock-in mice: an animal model of Autism. *Front. Cell. Neurosci.* **7**, 85. <https://doi.org/10.3389/fncel.2013.00085> (2013).
35. Cellot, G. & Cherubini, E. Reduced inhibitory gate in the barrel cortex of Neuroligin3R451C knock-in mice, an animal model of autism spectrum disorders. *Physiol. Rep.* <https://doi.org/10.14814/phy.12077> (2014).
36. Rock, R. B. *et al.* Role of microglia in central nervous system infections. *Clin. Microbiol. Rev.* **17**, 942–964. <https://doi.org/10.1128/CMR.17.4.942-964.2004> (2004).
37. Sofroniew, M. V. & Vinters, H. V. Astrocytes: biology and pathology. *Acta Neuropathol.* **119**, 7–35. <https://doi.org/10.1007/s00401-009-0619-8> (2010).
38. Kim, Y. S. & Joh, T. H. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. *Exp. Mol. Med.* **38**, 333–347. <https://doi.org/10.1038/emmm.2006.40> (2006).
39. Rodriguez, J. J., Witton, J., Olabarria, M., Noristani, H. N. & Verkhratsky, A. Increase in the density of resting microglia precedes neuritic plaque formation and microglial activation in a transgenic model of Alzheimer's disease. *Cell Death Dis.* <https://doi.org/10.1038/cddis.2009.2> (2010).
40. Perea, G., Navarrete, M. & Araque, A. Tripartite synapses: astrocytes process and control synaptic information. *Trends Neurosci.* **32**, 421–431. <https://doi.org/10.1016/j.tins.2009.05.001> (2009).
41. Pirttimaki, T. M. & Parri, H. R. Astrocyte plasticity: implications for synaptic and neuronal activity. *Neuroscientist* **19**, 604–615. <https://doi.org/10.1177/1073858413504999> (2013).

42. Ostroff, L. E., Manzur, M. K., Cain, C. K. & Ledoux, J. E. Synapses lacking astrocyte appear in the amygdala during consolidation of Pavlovian threat conditioning. *J. Comp. Neurol.* **522**, 2152–2163. <https://doi.org/10.1002/cne.23523> (2014).
43. Murai, K. K., Nguyen, L. N., Irie, F., Yamaguchi, Y. & Pasquale, E. B. Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling. *Nat. Neurosci.* **6**, 153–160. <https://doi.org/10.1038/nn994> (2003).
44. Nishida, H. & Okabe, S. Direct astrocytic contacts regulate local maturation of dendritic spines. *J. Neurosci.* **27**, 331–340. <https://doi.org/10.1523/JNEUROSCI.4466-06.2007> (2007).
45. Song, J. Y., Ichtchenko, K., Sudhof, T. C. & Brose, N. Neuroligin 1 is a postsynaptic cell-adhesion molecule of excitatory synapses. *Proc. Natl. Acad. Sci. USA* **96**, 1100–1105 (1999).
46. Varoqueaux, F., Jamain, S. & Brose, N. Neuroligin 2 is exclusively localized to inhibitory synapses. *Eur. J. Cell. Biol.* **83**, 449–456. <https://doi.org/10.1078/0171-9335-00410> (2004).
47. Poulopoulos, A. *et al.* Homodimerization and isoform-specific heterodimerization of neuroligins. *Biochem. J.* **446**, 321–330. <https://doi.org/10.1042/BJ20120808> (2012).
48. Sheng, M. & Kim, E. The postsynaptic organization of synapses. *Cold Spring Harb. Perspect. Biol.* <https://doi.org/10.1101/cshperspect.a005678> (2011).
49. Irie, M. *et al.* Binding of neuroligins to PSD-95. *Science* **277**, 1511–1515. <https://doi.org/10.1126/science.277.5331.1511> (1997).
50. Dresbach, T., Neef, A., Meyer, G., Gundelfinger, E. D. & Brose, N. Synaptic targeting of neuroligin is independent of neurexin and SAP90/PSD95 binding. *Mol. Cell. Neurosci.* **27**, 227–235. <https://doi.org/10.1016/j.mcn.2004.06.013> (2004).
51. Rizo, J. & Rosenmund, C. Synaptic vesicle fusion. *Nat. Struct. Mol. Biol.* **15**, 665–674 (2008).
52. Abrahams, B. S. *et al.* SFARI Gene 2.0: a community-driven knowledgebase for the autism spectrum disorders (ASDs). *Mol. Autism* **4**, 36. <https://doi.org/10.1186/2040-2392-4-36> (2013).
53. Baker, K. *et al.* SYT1-associated neurodevelopmental disorder: a case series. *Brain* **141**, 2576–2591. <https://doi.org/10.1093/brain/awy209> (2018).
54. Guerini, F. R. *et al.* SNAP-25 single nucleotide polymorphisms are associated with hyperactivity in autism spectrum disorders. *Pharmacol. Res.* **64**, 283–288. <https://doi.org/10.1016/j.phrs.2011.03.015> (2011).
55. Safari, M. R. *et al.* Synaptosome-associated protein 25 (SNAP25) gene association analysis revealed risk variants for ASD Iranian population. *J. Mol. Neurosci.* **61**, 305–311. <https://doi.org/10.1007/s12031-016-0860-2> (2017).
56. Braida, D. *et al.* Association between SNAP-25 gene polymorphisms and cognition in autism: functional consequences and potential therapeutic strategies. *Transl. Psychiatry* **5**, e500. <https://doi.org/10.1038/tp.2014.136> (2015).
57. Tomasoni, R. *et al.* SNAP-25 regulates spine formation through postsynaptic binding to p140Cap. *Nat. Commun.* **4**, 2136. <https://doi.org/10.1038/ncomms3136> (2013).
58. Paolicelli, R. C. *et al.* Synaptic pruning by microglia is necessary for normal brain development. *Science* **333**, 1456–1458. <https://doi.org/10.1126/science.1202529> (2011).
59. Abdolhoseini, M., Walker, F. & Johnson, S. Automated tracing of microglia using multilevel thresholding and minimum spanning trees. *Conf. Proc. IEEE Eng. Med. Biol. Soc.* **1208–1211**, 2016. <https://doi.org/10.1109/EMBC.2016.7590922> (2016).
60. Abdolhoseini, M., Kluge, M. G., Walker, F. R. & Johnson, S. J. Segmentation, tracing, and quantification of microglial cells from 3D image stacks. *Sci. Rep.* **9**, 8557. <https://doi.org/10.1038/s41598-019-44917-6> (2019).

Acknowledgements

This study was supported by the following funding sources: National Health and Medical Research Council project grant to P.J.C, Australian Research Council Future Fellowship (FT160100126) and RMIT Vice-Chancellor's Senior Research Fellowship to E.L.H-Y.

Author contributions

S.M.M. performed the experiments, interpreted the data and drafted the manuscript; P.J.C. and E.L.H-Y. conceptualised and designed the study, and interpreted the data; F.R.W. developed the algorithm for morphological analysis and assisted S.M.M with data analyses in this study; Z.M assisted with data analyses in this study. All authors contributed to the writing of the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41598-020-71171-y>.

Correspondence and requests for materials should be addressed to P.J.C.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.